Unveiling the roles of CTRP family in cardiac remodeling
Shuhong Zhao1,2, Dan Huang1,2, Rong Huang1,2
1Department of Cardiology, Renmin Hospital of Wuhan University, 430060, Wuhan, People's Republic of China.
Abstract:
The C1q/TNF-related protein family (CTRPs), a group of adipokines sharing structural homology with adiponectin (APN), have emerged as crucial regulators of metabolic and cardiovascular homeostasis. As secreted proteins with pleiotropic functions, CTRPs are involved in various physiological and pathological processes through autocrine, paracrine, and endocrine mechanisms. Cardiac remodeling, a central pathological process in cardiovascular diseases (CVDs) triggered by various cardiac injuries, involves structural and functional alterations in the myocardium. Emerging evidence has demonstrated that CTRPs play dual roles in cardiac remodeling, either ameliorating or exacerbating this process. Mechanistically, CTRPs modulate oxidative stress, inflammation, and metabolic reprogramming, all of which regulate cardiac hypertrophy and fibrosis. This review provides a systematic overview of the functional roles of CTRPs in cardiac remodeling, with a focus on their structural features, tissue distribution, and receptor-mediated signaling pathways. Furthermore, we discuss the therapeutic potential of CTRPs as biomarkers and molecular targets in CVDs, emphasizing the necessity of mechanistic and translational studies to advance clinical applications. The elucidation of CTRP-mediated pathways may offer novel insights into the pathogenesis of cardiac remodeling and facilitate the development of therapeutic strategies for treating CVDs.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TGF - β Signaling Pathway
Cardiomyopathy III: Hypertrophic Cardiomyopathy


